Finoriq research workspace
Aclaris Therapeutics, Inc. (ACRS) SEC Filings & Filing Highlights
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the. Review ACRS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
- Company
- Aclaris Therapeutics, Inc. (ACRS)
- Ticker
- ACRS
- Market Cap
- $782.8M
- Latest Price
- $5.605
- Industry
- Biotech & Pharma
Aclaris Therapeutics, Inc. (ACRS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aclaris Therapeutics, Inc. (ACRS).
| Event | Form | Date |
|---|---|---|
| Aclaris Therapeutics, Inc.: Shareholder voteOn June 4, 2026, Aclaris Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockh... | 8-K5.07 | 2026-06-04 |
| Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Cl...Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update | 8-K2.02 | 2026-05-07 |
| Clinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Com...Clinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Complete Therapy for Lichen Planus April 28, 20... | 8-K8.01 | 2026-04-28 |
| Clinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Com...Clinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Complete Therapy for Lichen Planus April 28, 20... | 8-K7.01 | 2026-04-28 |
| On March 10, 2026, Aclaris Therapeutics, Inc. sold 5.7 million shares of its common stock, for...On March 10, 2026, Aclaris Therapeutics, Inc. (the “Company”) sold 5.7 million shares of its common stock, for aggregate gross proceeds of... | 8-K7.01 | 2026-03-11 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.